# A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects

> **NCT01396135** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CP-601,927
- **DRUG:** CP-601,927
- **DRUG:** CP-601,927
- **DRUG:** Placebo
- **DRUG:** CP-601,927
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01396135
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08-26
- **Primary completion:** 2011-10-29
- **Final completion:** 2011-10-29
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396135, "A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01396135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*